IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
August 19 2022 - 9:20AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company focused on the discovery and development of innovative
gamma-delta T cell therapies utilizing its DeltEx platform, today
announced that the underwriter of its previously announced
underwritten public offering of common stock which closed on August
16, 2022 has partially exercised its option to purchase an
additional 268,949 shares at the public offering price of $1.90 per
share, resulting in additional gross proceeds of approximately $0.5
million. After giving effect to the partial exercise of the option
to purchase additional shares, the total number of shares sold by
IN8bio in the public offering increased to 5,663,686 shares and
gross proceeds increased to approximately $10.75 million.
H.C. Wainwright & Co. acted as the sole book-running manager
for the offering.
The shares were offered by IN8bio pursuant to a registration
statement on Form S-1 (File No. 333-266620) that was previously
filed with, and subsequently declared effective on August 11, 2022,
by the U.S. Securities and Exchange Commission (SEC). The offering
was made only by means of a prospectus that formed a part of the
effective registration statement. The final prospectus relating to
and describing the terms of the offering was filed with the SEC on
August 12, 2022. Electronic copies of the final prospectus may be
obtained by contacting H.C. Wainwright & Co., LLC, 430
Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212)
856-5711 or email at placements@hcwco.com. The final prospectus is
also available on the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of IN8bio, nor shall
there be any sale of these shares of common stock in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T cell product candidates for
solid and liquid tumors. Gamma-delta T cells are a specialized
population of T cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors:Solebury TroutDavid Buck+ 1
646.378.2927dbuck@soleburytrout.com
Media:Burns McClellan, Inc.Katie Larch / Robert
Flamm, Ph.D.+1 212.213.0006klarch@burnsmc.com /
rflamm@burmsmc.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Sep 2024 to Oct 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Oct 2023 to Oct 2024